Curated News
By: NewsRamp Editorial Staff
September 08, 2026
NanoViricides' Ebola Drug Trial Registered in Africa, Dosing Imminent
TLDR
- NanoViricides secures early trial registration and dosing for NV-387 Ebola treatment, positioning ahead in antiviral market.
- Phase II adaptive trial for NV-387 begins with safety run-in, then randomized controlled efficacy evaluation in DRC.
- New oral antiviral NV-387 aims to treat Ebola and Mpox, potentially saving lives in outbreak regions.
- NV-387 mimics host features to trick viruses, offering a novel broad-spectrum approach against Ebola and other threats.
Impact - Why it Matters
This news matters because it represents a potential breakthrough in the treatment of Ebola, a deadly virus that has caused devastating outbreaks in Africa. If NV-387 proves effective, it could provide a much-needed therapeutic option for Ebola patients, potentially reducing mortality rates and helping to contain future outbreaks. Additionally, the drug's broad-spectrum antiviral properties could have implications for treating other viral infections, including Mpox and COVID, making it a versatile tool in the global fight against infectious diseases. For investors, this progress in clinical trials could signal a promising future for NanoViricides, but it also highlights the lengthy and capital-intensive nature of drug development.
Summary
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage developer of antiviral drugs, has announced a significant step forward in its fight against Ebola. The company's phase II clinical trial for NV-387 Oral Gummies, intended to treat Bundibugyo ebolavirus and other Ebola viruses in the Democratic Republic of Congo (DRC), has been officially registered in the Pan African Clinical Trials Registry under the identification number PACTR202608748555077. This registration follows local regulatory approval from ACOREP and the delivery of NV-387 to the clinical trial site in Ituri province. First patient dosing is anticipated within one to two weeks, barring any outbreak-related impediments. The adaptive trial will commence with a single-arm safety and dose run-in phase before progressing to a randomized, controlled, open-label efficacy evaluation. NV-387 is an orally administered broad-spectrum antiviral designed to mimic host-side features that viruses require for infection, and it is also being evaluated in a phase II clinical trial for Mpox in the DRC.
NanoViricides is a clinical-stage company specializing in creating special purpose nanomaterials for antiviral therapy. Their novel nanoviricide(TM) class of drug candidates is based on technology licensed from TheraCour Pharma, Inc. The company's lead drug candidate, NV-387, is being developed as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and even Measles. The company is also developing drugs against a range of viral diseases including oral and genital Herpes, viral eye diseases, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus. For more details, the full press release is available at https://nnw.fm/UiQUn. Investors can find the latest news and updates regarding NNVC in the company's newsroom at https://nnw.fm/NNVC.
This development underscores NanoViricides' commitment to addressing urgent global health threats, particularly in regions affected by Ebola outbreaks. The company's innovative approach to antiviral therapy, using nanomedicine to mimic host-cell features, could potentially offer a broad-spectrum solution against multiple viral infections. With ongoing trials for both Ebola and Mpox, NanoViricides is positioning itself as a key player in the antiviral drug development landscape.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, NanoViricides' Ebola Drug Trial Registered in Africa, Dosing Imminent
